Twist Bioscience’s Financial Milestone: A Critical Quarter Ahead

Investors are preparing for a detailed look at Twist Bioscience’s operational health when the synthetic biology specialist releases its full first-quarter fiscal 2026 results. The report, scheduled for Monday, February 2, before U.S. markets open, follows preliminary revenue figures announced earlier in January. The central question for the market is whether the company’s path to profitability remains on track.

Beyond the core financials, strategic developments will be under scrutiny. Since December, a non-exclusive licensing agreement with Aptamer Group has been active. This collaboration is designed to integrate specialized binding agents into products for PCR and Next-Generation Sequencing, broadening the application of Twist’s core technology platform. Analysts view such partnerships Read more...